Tevogen Bio Holdings (TVGN) Change in Account Payables (2022 - 2026)
Tevogen Bio Holdings (TVGN) reported Change in Account Payables of $458472.0 for Q1 2026, up 185.62% on a YoY basis from $160520.5 in Q1 2025, and up 1526.02% quarter-over-quarter from $28196.0 in Q4 2025.
Tevogen Bio Holdings (TVGN) Change in Account Payables (2022 - 2026) Analysis & Trends
Tevogen Bio Holdings has reported Change in Account Payables for 5 years, with the latest figure at $458472.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables rose 185.62% year-over-year to $458472.0; the trailing twelve-month figure through Mar 2026 stood at -$970147.0 (down 77.31% YoY), and the FY2025 full-year result was -$2.0 million, down 216.52% from the prior year.
- Change in Account Payables for Q1 2026 stood at $458472.0, up from $28196.0 in the prior quarter.
- The five-year high for Change in Account Payables was $1.7 million in Q1 2024, with the low at -$1.0 million in Q3 2025.
- Historically, Change in Account Payables has averaged $83194.5 across 5 years, with a median of $30000.0 in 2022.
- The largest YoY upside for Change in Account Payables was 1558.28% in 2023 against a maximum downside of 516.23% in 2023.
- Tevogen Bio Holdings' Change in Account Payables stood at $30000.0 in 2022, then soared by 1065.42% to $349625.0 in 2023, then plunged by 282.51% to -$638117.0 in 2024, then soared by 104.42% to $28196.0 in 2025, then surged by 1526.02% to $458472.0 in 2026.
- The last three Change in Account Payables figures came in at $458472.0 (Q1 2026), $28196.0 (Q4 2025), and -$1.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Tevogen Bio Holdings | 173.69 Mn | 173.00 Mn | - | 458,472.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 458,472.00 |
| Mar 31, 2026 | 458,472.00 |
| Dec 31, 2025 | 28,196.00 |
| Dec 31, 2025 | 28,196.00 |
| Sep 30, 2025 | -1.03 Mn |
| Sep 30, 2025 | -1.03 Mn |
| Jun 30, 2025 | -424,444.00 |
| Jun 30, 2025 | -424,444.00 |
| Mar 31, 2025 | -535,499.00 |
| Mar 31, 2025 | -535,499.00 |
| Dec 31, 2024 | -638,117.00 |
| Dec 31, 2024 | -638,117.00 |
| Sep 30, 2024 | -827,867.00 |
| Sep 30, 2024 | -827,867.00 |
| Jun 30, 2024 | 1.45 Mn |
| Jun 30, 2024 | 1.45 Mn |
| Mar 31, 2024 | 1.70 Mn |
| Mar 31, 2024 | 1.70 Mn |
| Dec 31, 2023 | 349,625.00 |
| Dec 31, 2023 | 349,625.00 |